• Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis 

      Holmøy, Trygve; Fevang, Børre; Olsen, David Benee; Spigset, Olav; Bø, Lars (Journal article; Peer reviewed, 2019)
      Objective Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of ...
    • Impaired HDL function amplifies systemic inflammation in common variable immunodeficiency 

      Macpherson, Magnhild Eide; Halvorsen, Bente; Yndestad, Arne; Ueland, Thor; Mollnes, Tom Eirik; Berge, Rolf Kristian; Rashidi, Azita; Otterdal, Kari; Gregersen, Ida; Kong, Xiang Yi; Holven, Kirsten Bjørklund; Aukrust, Pål; Fevang, Børre; Jørgensen, Silje Fjellgård (Journal article; Peer reviewed, 2019)
      Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, characterized by inadequate antibody responses and recurrent bacterial infections. Paradoxically, a majority of CVID patients ...
    • Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency 

      Jørgensen, Silje Fjellgård; Macpherson, Magnhild Eide; Bjørnetrø, Tonje; Holm, Kristian; Kummen, Martin; Rashidi, Azita; Michelsen, Annika; Lekva, Tove; Halvorsen, Bente; Trøseid, Marius; Mollnes, Tom Eirik; Berge, Rolf Kristian; Yndestad, Arne; Ueland, Thor; Karlsen, Tom Hemming; Aukrust, Pål; Hov, Johannes Espolin Roksund; Fevang, Børre (Journal article; Peer reviewed, 2019)
      Common variable immunodeficiency (CVID) patients have reduced gut microbial diversity compared to healthy controls. The reduced diversity is associated with gut leakage, increased systemic inflammation and ten “key” bacteria ...